PETALUMA, Calif.--(BUSINESS WIRE)--Oculus Innovative Sciences, Inc. (Nasdaq:OCLS) announced today that the Indian Medical Gazette has published results from a randomized and controlled study of the company’s Microcyn® Technology in 50 patients in India for the management of wounds in post-caesarean section. In this study, Oxum (Microcyn formulation branded for India) demonstrated a benefit versus povidone iodine with respect to several efficacy endpoints including complete wound healing, healthy appearance, absence of odor, presence of granulation tissue, and lack of indolent stitches at the site of the wound. Oxum was found to be well tolerated and showed a modest advantage for the Oxum group over the control group. A reprint of the peer-reviewed paper, entitled “Comparative Efficacy and Tolerability of Oxum Against Povidone Iodine Topical Application in the Post-Caesarean Section Wound Management,” is available online at: http://www.oculusis.com/oxum_study.pdf.
